Longevity Repriced 100x
−5.4%
since Oct 3
The idea
I believe longevity therapies, from GLP-1s to gene editing and cellular reprogramming, are priced as niche biotech when they're actually gearing up for one of the largest markets that will exist, playing out over a decade. The basket blends proven GLP-1 and genetic-medicine leaders as ballast, picks-and-shovels tools like sequencing and AI drug discovery that win regardless of which therapy succeeds, and roughly a third in deliberately binary clinical-stage bets sized by odds times payoff, where failure means zero but success means a steep reprice.
What it owns
- Zero-or-huge clinical bets on editing, reprogramming and aging biology where success transforms the take's payoff. · Intellia TherapeuticsIt is the furthest along at editing genes inside the body, and its lead programs either reach approval and validate in-vivo editing or question the entire platform., Beam TherapeuticsIt uses base editing to change single DNA letters without cutting the strand, a cleaner approach that either works in people and reprices or fails entirely., Prime MedicineIt owns prime editing, the most precise and least proven editing technology in the take, a highest-payoff-if-it-works bet dependent on advancing human data and funding., Sana BiotechnologyIt is trying to build cells the immune system won't reject, and if hypoimmune technology works it reprices many times over as a platform for replacing worn-out tissue., BioAge LabsIt is the one position aimed directly at the biology of aging itself, using human longevity data to pick targets, either producing a drug that measurably extends healthspan or worth roughly its cash.28%
- The first drugs proven to extend healthy life at scale, already generating the cash that funds the rest of the take. · Eli LillyIt dominates the GLP-1 market with Zepbound and Mounjaro, and its pipeline pushes these drugs toward broader healthspan claims like heart and kidney outcomes., Novo NordiskIt pairs with Lilly as the other half of the GLP-1 duopoly, with Wegovy and Ozempic generating the cash that proves healthspan drugs can be one of the largest markets., Viking TherapeuticsIt is a binary bet on whether its dual-agonist obesity drug posts data good enough to compete with Lilly and Novo in the largest prize on the board., Structure TherapeuticsIt bets that a convenient oral pill can grab a real slice of the GLP-1 market, and either holds up against rivals on weight loss and tolerability or has little underneath.24%
- Sequencing, lab tools and AI discovery get paid whichever longevity therapy ends up winning. · Tempus AIIt builds the clinical and molecular data layer that AI drug discovery and precision medicine run on, scaling with healthspan medicine adoption., IlluminaIt still sells most of the DNA sequencing machines that nearly every therapy in this basket gets discovered and developed on top of., Thermo Fisher ScientificIt sells the instruments, reagents and manufacturing services every biotech in this basket pays for, and belongs as long as life-science spending keeps growing., Recursion PharmaceuticalsIt bets that AI can industrialize finding drugs, compressing the cost and time of every longevity therapy, and needs its platform to produce clinical wins or partnered milestones.20%
- Profitable or de-risked genetics-driven companies that benefit from the same longevity repricing with lower downside risk. · CRISPR TherapeuticsIt holds the first approved gene-editing medicine in Casgevy, proving that editing can become a real commercial market, and its in-vivo pipeline advances the frontier., Regeneron PharmaceuticalsIt turns one of the largest human genetic databases into drugs, providing the large-cap way to own genetic medicine as an engine of healthspan extension., Vertex PharmaceuticalsIt fixes diseases at their molecular root across cystic fibrosis, the Casgevy partnership and non-opioid pain, funding it all with durable cash flow.19%
- Early detection extends average lifespan directly and is the cheapest healthspan win available today. · GrailIt catches cancer from a blood draw before symptoms, one of the most direct ways to raise average age at death through early detection., Guardant HealthIt makes liquid biopsy routine across cancer treatment guidance and its Shield blood test for colon cancer screening, extending healthspan through early detection.9%